Latest Pharma and Biotech News
Pharmaceutical
12 December 2024 Eli Lilly has announced Phase III results for imlunestrant, its investigational oral selective estrogen receptor degrader (SERD), in breast cancer.
Today's issue
Refine Search
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its December meeting. 14 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Biotechnology
US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the autoimmune space. 13 December 2024
Biosimilars
The HSE University BRICS Competition Law and Policy Centre has summarized the first results of its annual analytical study on bringing biologics to the BRICS market. 13 December 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at its December 2024 meeting, bringing the total number of medicines recommended for approval in 2024 to 114. 13 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has published its annual report examining price increases for top-selling drugs in the USA, pointing to $815 million in prices hikes which it says are not clinically supported. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Pharmaceutical
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). 13 December 2024
Pharmaceutical
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
Pharmaceutical
Spanish plasma-based medicines producer Grifols has announced the execution of an agreement for a private placement of 1.3 billion euros ($1.4 billion) of 7.125% senior secured notes due May 2030 at par. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Biotechnology
Poland-based drug developer Ryvu Therapeutics, a clinical-stage drug discovery biotech, yesterday provided an update on clinical progress and data in the Phase II programRVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies. 13 December 2024
Pharmaceutical
Based on its review of post-market clinical trial data, the US Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
All news
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its December meeting. 14 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Biotechnology
US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the autoimmune space. 13 December 2024
Biosimilars
The HSE University BRICS Competition Law and Policy Centre has summarized the first results of its annual analytical study on bringing biologics to the BRICS market. 13 December 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at its December 2024 meeting, bringing the total number of medicines recommended for approval in 2024 to 114. 13 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has published its annual report examining price increases for top-selling drugs in the USA, pointing to $815 million in prices hikes which it says are not clinically supported. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Pharmaceutical
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). 13 December 2024
Pharmaceutical
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
Pharmaceutical
Spanish plasma-based medicines producer Grifols has announced the execution of an agreement for a private placement of 1.3 billion euros ($1.4 billion) of 7.125% senior secured notes due May 2030 at par. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Biotechnology
Poland-based drug developer Ryvu Therapeutics, a clinical-stage drug discovery biotech, yesterday provided an update on clinical progress and data in the Phase II programRVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies. 13 December 2024
Pharmaceutical
Based on its review of post-market clinical trial data, the US Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze